Malignant neoplasm of prostate
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Therefore, a systematic review was performed to explore the relationship of PITX2 methylation with the BCR risk of prostate cancer.
|
30608394 |
2019 |
Malignant neoplasm of prostate
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
PITX2 methylation discriminated between neoplastic and nonneoplastic tissue in patients with PCa (P < 0.001).
|
27939865 |
2017 |
Malignant neoplasm of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
Methylation was quantified by pyrosequencing assays for six genes (HSPB1, CCND2, TIG1, DPYS, PITX2, and MAL) with established biomarker value in prostate cancer.
|
27708246 |
2016 |
Malignant neoplasm of prostate
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The PITX2 gene expression level in prostate cancer tissues was lower than that in benign tissues.
|
27173224 |
2016 |
Malignant neoplasm of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
To explore differential methylation of HAAO, HOXD3, LGALS3, PITX2, RASSF1 and TDRD1 as a molecular tool to predict biochemical recurrence (BCR) in patients with high-risk prostate cancer (PCa).
|
24938434 |
2014 |
Malignant neoplasm of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our findings, which significantly expand previous evidence that PITX2 is associated with risk of PCa biochemical recurrence, indicate that variation in PITX2 expression accompanies and may promote prostate tumor progression and metastasis.
|
24162257 |
2014 |
Malignant neoplasm of prostate
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Moreover, it is unknown so far how PITX2 hypermethylation relates to other molecular changes in prostate cancer, such as ERG oncogenic activation in about half of all cases.
|
21803613 |
2013 |
Malignant neoplasm of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recently, a diagnostic microarray for prostate cancer prognosis based on PITX2 methylation has been developed and validated.
|
23266319 |
2013 |
Malignant neoplasm of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
Global methylation analysis identifies PITX2 as an upstream regulator of the androgen receptor and IGF-I receptor genes in prostate cancer.
|
22495974 |
2012 |
Malignant neoplasm of prostate
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
GSTP1, APC, RARβ2 and PITX2 methylation occur frequently in prostate cancer, making these markers sensitive tools for the detection of neoplastic lesions in the prostate.
|
21116117 |
2010 |
Malignant neoplasm of prostate
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Associations between PITX2 methylation and biochemical recurrence were assessed using the log rank test and Cox regression controlling for prostate cancer features.
|
20478579 |
2010 |
Malignant neoplasm of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
DNA methylation of PITX2 has been established in several studies as a prognostic biomarker for breast and prostate cancer.
|
20304943 |
2010 |
Malignant neoplasm of prostate
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
DNA methylation of the PITX2 gene promoter region is a strong independent prognostic marker of biochemical recurrence in patients with prostate cancer after radical prostatectomy.
|
19233404 |
2009 |